ULTRAVATE (halobetasol propionate) by Lacer is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 2015.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
ULTRAVATE (halobetasol propionate) is a potent topical corticosteroid lotion approved for treating plaque psoriasis. The precise mechanism in psoriasis remains unknown, though it modulates immune signaling, inflammation, and protein regulation. It represents a established topical therapy in the dermatology market.
Product remains in peak commercial phase with stable market position, though teams should prepare for competitive and generic pressures as LOE approaches in 6.7 years.
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis
Worked on ULTRAVATE at Lacer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on ULTRAVATE offers stable, commercially-focused career experience in a mature dermatology asset with established market presence. As the product approaches LOE, career trajectory depends on ability to drive defensive strategies, customer retention, and potential lifecycle management initiatives.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo